Eli Lilly and Company (LLY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Eli Lilly and Company (LLY) Healthcare & Pipeline Overview

Eli Lilly and Company is a prominent player in the global pharmaceutical industry, known for its extensive portfolio of innovative drugs targeting diabetes, oncology, and mental health, supported by a robust R&D pipeline and strategic collaborations.

What Is the Investment Thesis for LLY?

Eli Lilly's market capitalization of $1.21T and a P/E ratio of 42.8 reflect strong investor confidence in its growth prospects. The company's impressive profit margin of 35.0% and gross margin of 83.5% indicate robust operational efficiency. Key growth catalysts include the expansion of its diabetes portfolio, particularly with Trulicity, and the ongoing development of innovative cancer treatments. Eli Lilly's strategic collaborations with leading biotech firms enhance its research capabilities and accelerate the development of new therapies. However, potential risks include regulatory challenges and competition from generic drugs, which could impact future revenue growth. Overall, Eli Lilly's strong financial metrics and commitment to innovation position it well for sustained growth in the pharmaceutical sector.

Based on FMP financials and quantitative analysis

LLY Key Highlights

Market capitalization of $1.21T reflects strong market confidence and growth potential.

• P/E ratio of 42.8 indicates investor expectations for continued earnings growth.
• Profit margin of 35.0% showcases operational efficiency and profitability.
• Gross margin of 83.5% exceeds industry averages, highlighting effective cost management.
• Dividend yield of 0.57% offers a return to shareholders while maintaining reinvestment in R&D.

Who Are LLY's Competitors?

LLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LLY's Key Strengths?

Strong financial performance with high profit and gross margins.

• Diverse and innovative product portfolio across multiple therapeutic areas.
• Established global presence with a strong distribution network.
• Commitment to R&D leading to a robust pipeline of new therapies.

What Are LLY's Weaknesses?

High dependency on a few key products for revenue generation.

• Potential for regulatory challenges impacting product approvals.
• Exposure to patent expirations leading to increased competition.
• Ongoing litigation risks associated with pharmaceutical products.

What Could Drive LLY Stock Higher?

Potential FDA approvals for new diabetes and oncology therapies in 2026.

• Strong sales growth from Trulicity and other diabetes medications.
• Continued expansion of partnerships with biotech firms to enhance R&D capabilities.
• Launch of new mental health products targeting unmet needs in 2026.
• Investment in global market expansion to capture emerging market opportunities.

What Are the Key Risks for LLY?

Rich valuation — a P/E of 42.8 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $34.9M recently.
• Regulatory challenges that may delay product approvals.
• Competition from generic drugs impacting revenue from key products.
• Market volatility affecting overall healthcare spending and pricing.
• Legal risks associated with patent disputes and product liability.

What Are the Growth Opportunities for LLY?

• With increasing diabetes prevalence, the company aims to enhance its market share through innovative formulations and patient-centric solutions.
• Eli Lilly's strong pipeline, including drugs like Alimta and Cyramza, positions it to capture significant market opportunities as new therapies gain regulatory approval.
• Mental Health Solutions: With rising awareness of mental health issues, the global mental health market is expected to grow to $240 billion by 2026. Eli Lilly's established products like Cymbalta and Emgality, along with ongoing research in this area, provide a solid foundation for capturing this expanding market.
• Eli Lilly's existing therapies, including Bamlanivimab, position the company to benefit from ongoing public health needs.
• Strategic Collaborations: Eli Lilly's partnerships with biotech firms enhance its research capabilities and accelerate the development of new therapies. By leveraging external innovations, the company can diversify its product offerings and maintain a competitive edge in the rapidly evolving pharmaceutical landscape.

What Opportunities Does LLY Have?

• Expansion into emerging markets with growing healthcare needs.
• Increased focus on personalized medicine and targeted therapies.
• Potential for growth in mental health and chronic disease management.
• Strategic acquisitions to enhance product offerings and market presence.

What Threats Does LLY Face?

• Intense competition from generic drug manufacturers.
• Regulatory changes impacting drug pricing and reimbursement.
• Market volatility affecting overall healthcare spending.
• Public scrutiny and potential backlash over drug pricing.

What Are LLY's Competitive Advantages?

• Strong brand recognition and reputation built over 140 years.
• Extensive patent portfolio protecting key products from generic competition.
• Robust R&D capabilities leading to innovative drug development.
• Established relationships with healthcare providers and payers.
• Diverse product portfolio addressing multiple therapeutic areas.

What Does LLY Do?

Founded in 1876, Eli Lilly and Company has established itself as a leader in the pharmaceutical industry, focusing on the discovery, development, and marketing of human pharmaceuticals worldwide. Headquartered in Indianapolis, Indiana, the company has grown significantly over the years, evolving from a small drug manufacturer to a global powerhouse with a workforce of approximately 47,000 employees. Eli Lilly's product offerings include a wide range of medications for various therapeutic areas, including diabetes, oncology, immunology, and mental health. Notable products include Humalog and Trulicity for diabetes management, Alimta for lung cancer, and Cymbalta for depression and anxiety disorders. The company has also made significant advancements in COVID-19 treatments with its monoclonal antibodies. Eli Lilly's commitment to innovation is further exemplified by its collaborations with various biotech firms, enhancing its research capabilities and expanding its product pipeline. The company operates in a highly competitive environment, facing challenges from established players and emerging biotech firms, but continues to leverage its strong brand reputation and extensive research capabilities to maintain its market position.

What Products and Services Does LLY Offer?

• Discover, develop, and market innovative pharmaceuticals for various diseases.
• Offer a comprehensive range of diabetes medications, including insulin and GLP-1 receptor agonists.
• Provide treatments for various cancers, including lung cancer and breast cancer.
• Develop therapies for mental health conditions, including depression and anxiety disorders.
• Engage in strategic collaborations to enhance research and development capabilities.
• Focus on patient-centric solutions and personalized medicine approaches.

How Does LLY Make Money?

• Generate revenue through the sale of patented pharmaceuticals and biologics.
• Invest heavily in research and development to drive innovation and pipeline expansion.
• Leverage strategic partnerships to enhance product offerings and market reach.
• Utilize a global distribution network to deliver products to healthcare providers and patients.
• Engage in direct-to-consumer marketing to raise awareness of key therapies.

What Industry Does LLY Operate In?

The pharmaceutical industry is experiencing significant growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. Eli Lilly operates in a competitive landscape alongside major players such as Johnson & Johnson, AbbVie, Merck, Novartis, and AstraZeneca. The company's focus on innovation and its strong product pipeline position it favorably within this dynamic industry, allowing it to capitalize on emerging market trends and consumer needs.

Who Are LLY's Key Customers?

• Healthcare providers, including hospitals and clinics.
• Pharmacies and retail chains distributing pharmaceuticals.
• Patients requiring chronic disease management and treatment.
• Government and private health organizations purchasing medications.
• Payers and insurance companies managing drug reimbursement.

Eli Lilly and Company (LLY) Valuation Context

Valued at $1.21T, LLY is classified as a mega-cap stock. Relative to its peer group, LLY's quantitative score of 97/100 is above the peer average of 73/100.

LLY Revenue & Earnings Trend

In Q2 2026, LLY generated $22.97B in top-line revenue, marking a sequential increase of 16.0%. The company recorded net income of $7.09B, with diluted EPS of $7.94. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mega-cap Healthcare company. Across the four most recent quarters, LLY averaged $7.45 in diluted EPS.

Company Profile

Eli Lilly and Company operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Indianapolis, US. The company is led by CEO David A. Ricks. LLY has traded publicly since 1972.

Return on equity for Eli Lilly and Company stands at 101.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 21.7%, showing how much profit it generates from its asset base. LLY trades at a trailing price-to-earnings ratio of 42.84, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.50 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.3%, the inverse of the P/E and a quick read on earnings relative to price.

Eli Lilly and Company's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.20 places it in the safe zone, indicating low near-term bankruptcy risk.

Eli Lilly and Company has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 10.9% above estimates on average.

Wall Street analysts project Eli Lilly and Company revenue of about $86.76B for fiscal 2026, with EPS near $36.13. The estimate reflects 13 contributing analysts.

Over the past six months, Eli Lilly and Company insiders filed 30 SEC Form 4 transactions — 8 sales and 22 purchases. On net that is roughly 32K shares disposed (about $34.9M), a signal worth weighing alongside the fundamentals.

LLY Financials

LLY Latest News

LLY Analyst Consensus

LLY MoonshotScore

Latest Eli Lilly and Company Analysis

Related Investment Themes

Eli Lilly and Company Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources